Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease

Giuseppe Di Lorenzo, S. De Placido, R. Autorino, M. De Laurentiis, C. Mignogna, M. D'Armiento, G. Tortora, G. De Rosa, M. D'Armiento, M. De Sio, A. R. Bianco, F. P. D'Armiento

Research output: Contribution to journalArticlepeer-review


Objectives: To determine whether COX-2, bcl-2 and neoangiogenesis are related to human prostate cancer relapse after definitive surgical treatment and progression toward androgen independence and to evaluate the association between the patterns of these tumoral biomarkers and other standard clinico-pathological parameters (such as Gleason score, PSA, TNM stage). Materials and methods: We retrospectively analyzed the records on 126 prostate cancer samples from patients treated at our University Hospital from 1995 to 2002. The 72 patients with clinically localized disease (group 1) had undergone radical prostatectomy. Another 54 patients (group 2) had metastatic androgen-independent disease. Archived material relating to the subjects was then immunostained for bcl-2, COX-2 and CD-31, using an anti-bcl-2 monoclonal primary antibody, an anti-COX-2 polyclonal rabbit antibody and an anti-CD-31 monoclonal mouse antibody to evaluate neoangiogenesis (MVD, microvessel density). Results: We found that bcl-2, COX-2 and MVD expression increased from group 1 to group 2. The intergroup difference was significant only for high MVD (P

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Issue number1
Publication statusPublished - Mar 2005


  • Bcl-2
  • COX-2
  • MVD
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease'. Together they form a unique fingerprint.

Cite this